Refractory Plasma Cell Myeloma
Refractory Plasma Cell Myeloma is a type of blood cancer that occurs when plasma cells in the bone marrow become cancerous and do not respond to standard treatments, leading to persistent disease symptoms.
Myeloma Treatment: SAR446523 Injection
We are investigating a new injection for adults with relapsed or refractory myeloma. The study aims to determine its safety and effectiveness compared to current treatments.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Centre Hospitalier Universitaire De Lille
Service des Maladies du Sang
La Madeleine, France
Centre Hospitalier Universitaire De Nantes
Service d'hématologie clinique
Nantes, France
Azienda Ospedaliero Universitaria Delle Marche
Clinica Ematologica
Ancona, Italy
Sponsor: Sanofi-Aventis Recherche & Developpement
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.